Business Wire

HAI ROBOTICS Marks Milestone with HAIPORT for Order Fulfillment Efficiency

14.12.2021 16:20:00 EET | Business Wire | Press release

Share

HAI ROBOTICS, a global leader in Autonomous Case-handling Robotics (ACR) system for warehouse fulfillment, marked a milestone for its solution of HAIPORT-powered Workstation -- with over 100 sets in operation globally since the product was launched one year ago. The solution has enormously improved order fulfillment efficiency for its customers who were pressured to update their warehousing facilities with higher throughput capacity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005725/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

HAIPORT-powered Workstation in a warehouse. (Photo: Business Wire)

HAIPORT is an automatic loading and unloading machine that can be docked with HAI ROBOTICS’ autonomous case-handling robots and conveyor workstations.

At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the HAIPORT loader, then transferred onto the conveyor belts for sorting per system orders and moved to the HAIPORT unloader, where they were fetched by robots for the next round of order processing.

The collaboration between HAIPICK robots, HAIPORT, and conveyor belt allows one-stop case-handling from in-bounds to out-bounds. The solution boasts obvious advantages by increasing the throughput of a warehouse.

With case loading and unloading being processed simultaneously at the two sides of a HAIPORT, a single workstation can be expected to handle up to 900 cases per hour, far exceeding that of manual handling. The speed is 16 times faster than the robot-to-conveyor belt transport.

The speed - four to eight cases being loaded in 3 seconds and unloaded in 5s - promises higher case-handling capacity. A single robot’s efficiency can be improved by 30% compared with manual loading/unloading.

Designed to realize direct interaction between HAIPICK robot and conveyor belt, HAIPORT-powered workstation guarantees higher loading and unloading speeds with least human intervention, increasing manual picking efficiency up to 3 times. The use of the workstation can free warehouse staff from tedious manual labor so that they can focus on more important tasks.

Armed with HAI ROBOTICS’ software platform as well as the multi-sensor technology that can monitor a robot’s movement, the workstation can accurately judge if a particular case of goods should be delivered to a workstation or not. Its modular design also grants scalability and flexibility when automating a warehouse. It can be customized and adapted for different uses based on the customer’s requirements. As a result, 30% fewer robots are required if a HAIPORT-powered Workstation is deployed in a warehouse.

HAIPORT-powered workstation has been certified by CE and ETL in compliance with the safety standards for Europe and US markets, respectively. The certifications also evidence that HAI ROBOTICS has been implementing stringent quality control for its products along its own supply chain, in product design and production.

Jeff Zheng, R&D Director at HAI ROBOTICS, said, “HAIPORT-powered Workstation offers an innovative solution for warehousing automation and provides a new way of human-machine interaction. It helps not only increase operational efficiency, but also reduce costs and deliver better ROI. We’re committed to delivering more value to our customers and making their investments worthwhile.”

Thanks to its flexibility, HAIPORT-powered Workstation is suitable for extensive storage scenarios in which medium and small-sized cases are used, such as raw materials, small electronics, apparels, medicine, retails and 3PL industries that have large number of SKUs and demand high order fulfillment efficiency in peak hours with surging e-commerce demands.

About HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) system, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.

The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Anna Zhao
Overseas Brand Communications Manager
anna.zhao@hairobotics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye